AstraZeneca to buy US-listed Fusion Pharma for $2bn
Fusion Pharmaceuticals Inc
$21.42
10:59 26/04/24
0.09%
$0.02
AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.
AstraZeneca
11,988.00p
16:40 26/04/24
-0.32%
-38.00p
FTSE 100
8,139.83
17:09 26/04/24
n/a
n/a
FTSE 350
4,470.09
16:59 26/04/24
n/a
n/a
FTSE All-Share
4,423.59
17:14 26/04/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,773.26
16:59 26/04/24
0.10%
22.78
Fusion specialises in radioconjugates, which combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells.
AstraZeneca will pay $21 a share for Fusion, a premium of more than 97% to the US-listed company's closing price on Monday and a non-transferable contingent value right of $3 per share, taking the combined transaction value to about $2.4bn.
Reporting by Frank Prenesti for Sharecast.com